John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Immunotherapy in digestive tumors Volume 23, issue 10, Décembre 2016

Figures

  • Figure 1

Tables

Authors
Gustave Roussy,
Département d’Innovation Thérapeutique et Essais Précoces (DITEP),
114 rue Edouard Vaillant,
94800
Villejuif,
France
* Tirés à part

The new immunotherapies anti-CTLA4 et anti-PD-1/PD-L1 targeting immune checkpoints may induce sustained tumor responses and patient overall survival improvement. Following the dramatic results of anti-checkpoints inhibitors in melanoma, these new treatments were evaluated in other tumor types previously considered “immuno-resistant”. Thus, contrary to what was expected, the anti-PD-1 have shown efficacy in lung cancer, leading to their marketing registration. The evaluation of these molecules is still ongoing in gastrointestinal tumors. However, some results are particularly promising and announce their imminent arrival in different subtypes of digestive tumors.